WillItSurvive
Food tech and alternative protein · subsidiary of Novo Holdings A/S (Novo Nordisk Foundation holding company) · Denmark

Novozymes

novozymes.com ↗

Novonesis (Novozymes plus Chr. Hansen) makes enzymes and microbes for food, feed, and industry.

Hard to displace
Assessed 25 July 2026 · Evidence as of 25 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 25 July 2026 · Checkable from 2027-2030 · Every call on the record Checkpoint: BASF-IFF platform targets first commercial products
The call

Novonesis sits well ahead on scale and approvals while AI and rivals like BASF-IFF are still building tools rather than shipping enzymes that customers actually buy.

Novozymes produces enzymes, proteins that speed up chemical reactions, used in detergents, food production, and other industries. It is hard to replace because it has spent decades building libraries of microorganism strains, has regulatory approvals competitors would take years to match, and runs 32 factories worldwide that took enormous capital to build; new rivals and AI protein design tools can find enzyme sequences faster now, but they still cannot quickly get regulatory approval or manufacture at industrial scale. The biggest question is whether BASF and IFF's partnership, targeting 2027 to 2030, actually ships a competing product that takes away customers.

Why
01
AI pressure: Chai Discovery and other AI protein-design labs. AI protein design tools are speeding up pharma work now; industrial enzyme design still needs fermentation scale and regulatory dossiers AI can't shortcut yet. Could AI do the core job? Only partly.
02
Bigger players: BASF-IFF Designed Enzymatic Biomaterials partnership. BASF and IFF announced a joint enzyme platform in October 2025, aiming to commercialize by 2027 to 2030. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of strain libraries, 32 fermentation plants, and regulatory approvals that take years for anyone else to rebuild.
What would change this call
BASF-IFF 'Designed Enzymatic Biomaterials' platform ships a commercial product before 2028. Would show a major chemicals-flavor rival converting R&D into real enzyme-market competition.
dsm-firmenich completes its Animal Nutrition & Health sale to CVC and a new buyer expands feed-enzyme output. Would show whether feed-enzyme competition consolidates further toward Novonesis or a new rival emerges.
Chai Discovery or similar AI-protein labs announce a licensing deal for food or feed industrial enzymes, not pharma. Would show AI-native biotech actually entering Novonesis's core industrial-enzyme market.
Key numbers
  • Revenue EUR 4,157.6M in 2025, up from EUR 3,833.5M (2026-02)
  • 7% organic sales growth in 2025 (2026-02-25)
  • Adjusted EBITDA margin 37.1% (2026-02)
Named risks
  • Softening US consumer sentiment could push 2026 organic growth toward low end of 5-7% guidance. Severity: medium
  • AI-driven protein design compresses discovery timelines, potentially eroding R&D-based moat over time. Severity: medium
  • BASF-IFF enzyme platform could capture share once commercialized 2027-2030. Severity: low
  • Regulatory shortcuts collapsing GRAS dossier lead-times could lower barriers for new entrants. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
dsm-firmenichlosing toSold Feed Enzyme Alliance stake to Novonesis 2025; agreed EUR 2.2B Animal Nutrition divestiture Feb 2026
BASF/IFFcontestingAnnounced Designed Enzymatic Biomaterials R&D partnership Oct 2025, targeting 2027-2030 commercialization
Chai DiscoverycontestingAI-biotech signed Novartis, Eli Lilly antibody-discovery deals July 2026, currently pharma-focused not industrial enzymes
Questions people ask
Is Novozymes profitable in 2025?
Yes. As Novonesis (the merged entity), net profit was EUR 583.6 million in 2025, up from EUR 305.8 million in 2024, on net sales of EUR 4,157.6 million and a 37.1% adjusted EBITDA margin, reported February 2026.
Does Novozymes still exist as a separate company?
Not independently. Novozymes completed a statutory merger with Chr. Hansen on January 29, 2024, forming Novonesis. The legal entity trades as Novozymes A/S, Part of Novonesis Group, on Nasdaq Copenhagen under ticker NSIS-B.
Could AI replace Novozymes' enzyme discovery work?
AI has sped up parts of it: Novonesis's CEO said protein-shape prediction tasks that took about a year now take under a minute (Feb 2026). But regulatory dossiers, fermentation manufacturing at 32 sites, and customer integration remain unreplicated by AI as of 2026.
Who owns Novonesis, formerly Novozymes?
Novo Holdings A/S, the Novo Nordisk Foundation's holding company, is the majority controlling shareholder, a position it held in Novozymes before the January 29, 2024 merger with Chr. Hansen created Novonesis.
Who is Novonesis's biggest competitor?
dsm-firmenich is the closest rival but is retreating: it sold its Feed Enzyme Alliance stake to Novonesis in 2025 and agreed in February 2026 to divest Animal Nutrition & Health to CVC Capital Partners for EUR 2.2 billion. BASF and IFF are also partnering, targeting 2027 to 2030.
What is Novonesis's 2026 growth guidance?
Management guided to 5-7% organic sales growth and a 37-38% adjusted EBITDA margin for 2026, issued February 25, 2026, while flagging softening US consumer sentiment as a risk to hitting the top of that range.
Timeline
  • 2026-03-23Novonesis AGM finalizes 2026 resolutions with no governance disruptions
  • 2026-03-06dsm-firmenich agrees to divest Animal Nutrition & Health to CVC for EUR 2.2B
  • 2026-02-25Novonesis reports 7% organic growth for 2025, issues 5-7% 2026 guidance
  • 2026-02-20CEO letter cites 100% merger synergies achieved a year early, AI cutting protein prediction to under a minute
  • 2026-02Novonesis financial summary shows EUR 4,157.6M 2025 sales, EUR 583.6M net profit
  • 2025-11-11Novonesis and restaurant Noma launch flavor/fermentation food prototype partnership
  • 2025-09-17NSF awards Novonesis funding for AI-assisted enzyme design with Stanford and UC Davis
  • 2025Novonesis completes EUR 1.5B acquisition of dsm-firmenich's Feed Enzyme Alliance stake
  • 2024-02-02Settlement of Novozymes-Chr. Hansen combination completed, shares issued
  • 2024-01-29Novozymes and Chr. Hansen merger completes, forming Novonesis
Revision history
25 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Toyo Suisan Kaisha, Ltd.IOI Corporation BerhadBunge Global
More in Food tech and alternative protein →
Sources